{"id":"W4417114937","doi":"10.1111/all.70181","title":"Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria","year":2025,"lang":"en","type":"article","venue":"Allergy","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novartis Pharma; Genentech; National Institutes of Health; Eisai; Mitsubishi Tanabe Pharma Corporation; Celltrion; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Galderma; Eli Lilly and Company; AstraZeneca; CSL Behring; Aimmune Therapeutics; Taiho Pharmaceutical; LEO Pharma; BioMarin Pharmaceutical; Kaken Pharmaceutical; Sanofi; Amgen; Kyorin Pharmaceutical; Pfizer","keywords":"Immunopathology; MEDLINE; Chronic urticaria; Autoimmune disease; Angioedema; Allergy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001971663,0.000502178,0.001440266,0.0001888561,0.0002879032,0.0005667247,0.0003159461,0.0006710661,0.001273671],"category_scores_gemma":[0.00143178,0.0002058656,0.000828166,0.0001835102,0.0002898915,0.0005140084,0.0001980157,0.001373782,0.0003078294],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003646553,"about_ca_system_score_gemma":0.0005172944,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002095933,"about_ca_topic_score_gemma":0.0004619488,"domain_scores_codex":[0.9994733,0.0002379282,0.00005108305,0.00007052063,0.0000780914,0.00008911906],"domain_scores_gemma":[0.9989618,0.000282484,0.0003514112,0.00008849279,0.00008369465,0.0002320176],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5917868,0.03708467,0.02767497,0.001602818,0.002136497,0.0003779464,0.000426875,0.001803691,0.06272268,0.0001316314,0.002146971,0.2721044],"study_design_scores_gemma":[0.205157,0.6796602,0.09965033,0.0001717438,0.001140025,0.0009441457,0.0001047961,0.0018109,0.007607191,0.0001198664,0.003581813,0.00005208446],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958027,0.003151467,0.0001495165,0.00009490223,0.00002882795,0.000218476,0.000125314,0.00001998237,0.00040884],"genre_scores_gemma":[0.998008,0.0006678448,0.0002328134,0.0001711257,0.00005866817,0.0003198398,0.0002720914,0.000004476588,0.000265182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001971663,"threshold_uncertainty_score":0.0104273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00447194017327993,"score_gpt":0.2335508368203654,"score_spread":0.2290788966470854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}